Skip to content

filings.toolsA Dark Vector Cognition product

Item 6. SELECTED FINANCIAL DATA

2K characters. Original on sec.gov · Markdown

Item 6. SELECTED FINANCIAL DATA

**


		Year Ended December 31
		2018			2017			2016			2015			2014
Net sales (1)		$	30,578		$	27,390		$	20,853		$	20,405		$	20,247
Earnings from continuing operations (1)			2,334			353			1,063			2,606			1,721
Net earnings			2,368			477			1,400			4,423			2,284
Basic earnings per common share from continuing operations (1)			1.32			0.20			0.71			1.73			1.13
Basic earnings per common share			1.34			0.27			0.94			2.94			1.50
Diluted earnings per common share from continuing operations (1)			1.31			0.20			0.71			1.72			1.12
Diluted earnings per common share			1.33			0.27			0.94			2.92			1.49
Total assets			67,173			76,250			52,666			41,247			41,207
Long-term debt, including current portion			19,366			27,718			20,684			5,874			3,448
Cash dividends declared per common share			1.16			1.075			1.045			0.98			0.90

(1)

Amounts reflect Abbott's developed markets branded generics pharmaceuticals, animal health and former research-based pharmaceuticals business as discontinued operations.

Previous: Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES · Next: Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS